EGM
SYRE icon

Engineers Gate Manager’s Spyre Therapeutics SYRE Stock Holding History

Engineers Gate Manager’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Buy
+38,474
New +$2.81M 0.04% 462
2024
Q2 		– Sell
-15,653
Closed -$594K – 2232
2024
Q1 		$594K Buy
+15,653
New +$454K 0.02% 1110
2022
Q1 		– Sell
-600
Closed -$71K – 2296
2021
Q4 		$71K Buy
+600
New +$94.7K ﹤0.01% 1836
2021
Q2 		– Sell
-432
Closed -$86K – 2004
2021
Q1 		$86K Buy
+432
New +$82.9K ﹤0.01% 1723
2020
Q4 		– Sell
-576
Closed -$102K – 1975
2020
Q3 		$102K Buy
+576
New +$107K ﹤0.01% 1553

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Engineers Gate Manager's SYRE Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 38,474 shares worth $3.42M. The stake represents 0.04% of the portfolio and ranks #462 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in SYRE as recently as Q1 2024.

Engineers Gate Manager first reported a position in SYRE in Q3 2020 and has held it in 5 quarters since. 267 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Engineers Gate Manager held 38,474 shares of Spyre Therapeutics worth $3.42M as of Q2 2026.
  • Spyre Therapeutics was a new Engineers Gate Manager position in Q2 2026.
  • Spyre Therapeutics made up 0.04% of Engineers Gate Manager's portfolio in Q2 2026, its #462 holding.
  • Engineers Gate Manager first reported a position in Spyre Therapeutics in Q3 2020 and has held it in 5 quarters since.
  • 267 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.